Skip to main content

Advertisement

Table 2 Characteristics of treatment exposures included in the meta-analysis

From: Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment

Trial (year) Treatment group Treatment protocol
CRUISE (2010) IVR 0.5 mg (n = 130) IVR 0.5 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months
IVR 0.3 mg (n = 132) IVR 0.3 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months
Sham injection (n = 130) sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label) for 6 months
ROCC (2010) IVR 0.5 mg (n = 16) IVR 0.5 mg every month for 3 months, then as required (at the discretion of the physician) for persisting macular oedema
Sham injection (n = 16) sham injection (plastic syringe pressed against the eyeball)
BRAVO (2011) IVR 0.5 mg (n = 131) IVR 0.5 mg monthly injections then PRN (open-label) for 6 months
IVR 0.3 mg (n = 134) IVR 0.3 mg monthly injections then PRN (open-label) for 6 months
Sham injection (n = 132) sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label) for 6 months
Tan (2014) IVR 0.5 mg (n = 15) IVR 0.5 mg monthly injections up to month 5 then PRN for 6 months
Sham injection plus laser (n = 21) sham injection monthly up to month 5 then PRN for 6 months, laser at week 13 and 25 if eligible
  1. IVR = intravitreal ranibizumab; PRN = Pro Re Nata.